Related Experiment Video

Updated: Mar 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Drug resistance in lung cancer

Manish Shanker1, David Willcutts1, Jack A Roth1

  • 1Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA.

Lung Cancer (Auckland, N.Z.)
|February 18, 2017
PubMed

Insights

Chemotherapy drug resistance is a major challenge in cancer treatment, particularly lung cancer. This review summarizes common drug resistance mechanisms and highlights the need for new therapeutic targets to improve patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Chemotherapy drug resistance significantly impedes cancer treatment efficacy.
  • Recent advances have identified molecular mechanisms underlying cancer cell adaptation and survival against cytotoxic drugs.
  • Despite progress, 5-year survival for lung cancer remains low, indicating undiscovered resistance factors.

Purpose of the Study:

  • To review and summarize prevalent mechanisms of chemotherapy drug resistance in lung cancer.
  • To underscore the necessity for identifying novel therapeutic targets.
  • To provide a foundation for developing innovative strategies against drug resistance.

Main Methods:

  • Literature review of scientific advances in cancer drug resistance.
  • Analysis of identified genes and molecular signaling pathways contributing to resistance.
  • Synthesis of current knowledge on drug resistance mechanisms in lung cancer.

Main Results:

  • Detailed summary of common molecular mechanisms driving chemotherapy resistance in lung cancer.
  • Identification of gaps in current understanding of drug resistance.
  • Highlighting the ongoing development of targeted therapies.

Conclusions:

  • Understanding cancer cell adaptation is crucial for overcoming drug resistance.
  • Discovery of new targets is essential for developing innovative therapies.
  • Further research into drug resistance mechanisms is vital to improve lung cancer patient outcomes.
Keywords:
DNA damageapoptosischemotherapylung cancerproteasomeresistance

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K